Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MGTX vs DSGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGTX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

MGTX Overall Winner 6-Pillar Tally: MGTX 6 – 0 DSGN Matrix Metrics: MGTX 7 – 3 DSGN

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MGTX carries a Unified Composite Score of 43.7/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. MGTX 43.7/100 HOLD), MGTX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: MGTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MGTX vs DSGN
MGTX NASDAQ Head-to-Head Winner
MeiraGTx Holdings plc Ordinary Shares
Biological Products, (No Disgnostic Substances)
$8.85
-3.59% 1D
Market Cap $844.2M
TTM Revenue $398M
Forward P/E 64.1x
Beta / 30D Vol 1.65β · 68% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 33.0 Fund 58.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.7%), weak momentum, RSI 40
RSI-14: 40.5 · SMA20: $9.39 · SMA50: $10.61
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 55.0 Fund 57.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $10.53 · SMA50: $11.58

6-Pillar Scorecard Institutional Category Breakdown (MGTX 6 – 0 DSGN)

Columns: Metric · MGTX · DSGN
1. Valuation Multiples MGTX
Forward P/E 64.1x N/M
Trailing P/E 10.1x N/M
PEG Ratio N/M N/M
EV / Revenue 2.0x N/M
2. Growth & Scale MGTX
Revenue Growth (YoY) +8608.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $398M $33,000
Market Cap $844.2M $677.5M
3. Profitability & Quality MGTX
Gross Margin 97.9% N/A
Operating Margin 46.3% 0.0%
Net Profit Margin 19.9% 0.0%
Return on Equity (ROE) 72.2% -36.9%
4. Balance Sheet & Cash Flow MGTX
Cash Generation (TTM) -$28M -$59M
Cash Flow Margin -7.0% N/A
Net Cash / Leverage $51M Net Cash $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MGTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 52.9% (3rd %ile) 92.0% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat MGTX
OpEx & R&D Intensity 51.6% of Rev ($205M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MGTX (7) vs DSGN (3)
Institutional Metric MGTX DSGN Criterion Row Edge
Market Capitalization
Scale
$844.2M $677.5M Larger Scale MGTX
Trailing P/E Ratio
Valuation
10.1x N/M Lower Multiple MGTX
Forward P/E Ratio
Valuation
64.1x N/M Lower Multiple MGTX
Revenue Growth (YoY)
Growth
+8608.6% +0.0% Higher Growth MGTX
Operating Margin (TTM)
Profitability
46.3% 0.0% Higher Margin MGTX
Net Profit Margin
Profitability
19.9% 0.0% Higher Margin MGTX
Return on Equity (ROE)
Capital Efficiency
72.2% -36.9% Higher ROE MGTX
52-Week Range Position
Momentum
26% ($7–$15) 30% ($7–$17) Stronger Trend DSGN
Beta / 30D Volatility
Risk Regime
1.65β · 68% Vol 1.32β · 61% Vol Lower Realized Risk DSGN
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite DSGN
Trailing 12M Revenue (USD)
Operating Scale
$398M $33,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
97.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M ($51M Net Cash) -$59M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DSGN +1.04 pp
MGTX: -4.63% · DSGN: -3.59%
3M Horizon DSGN +1.38 pp
MGTX: -36.29% · DSGN: -34.91%
6M Horizon MGTX +1.25 pp
MGTX: -5.85% · DSGN: -7.1%
1Y Horizon DSGN +33.65 pp
MGTX: +7.14% · DSGN: +40.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MGTX Revenue DSGN Revenue MGTX Op. Margin DSGN Op. Margin Margin Leader
FY2019 $10M N/A -438.4% N/A MGTX
FY2020 $20M $0M -401.9% -3685.8% MGTX
FY2021 $40M N/A -193.0% N/A MGTX
FY2022 $20M N/A -730.9% N/A MGTX
FY2023 $10M N/A -977.8% N/A MGTX
FY2024 $30M N/A -493.4% N/A MGTX
FY2025 $80M N/A -130.2% N/A MGTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MGTX BREAKDOWN
62d in phase · OBV ACCUMULATION
Current IV 52.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MGTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MGTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $844.2M market capitalization and 46.3% operating margin.
OpEx & R&D Reinvestment 51.6% of Rev ($205M)
90D Engineering Disclosures 0 Published
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MGTX vs DSGN Key Questions & Quantitative Answers

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MGTX carries a Unified Composite Score of 43.7/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. MGTX 43.7/100 HOLD), MGTX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (46.3% vs. 0.0% operating margin) and revenue trajectory (+8608.6% vs. +0.0% YoY). Technical & Structure Timing Caution: MGTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MGTX leads the Growth & Scale pillar: MGTX posts +8608.6% YoY revenue growth and +0.0% YoY earnings growth on $398M TTM revenue (97.9% gross margin, 46.3% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MGTX cumulative revenue shifted +700.0% while DSGN shifted N/A. In operating R&D and SG&A reinvestment, MGTX deploys 51.6% of Rev ($205M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.

MGTX screens cheaper on headline valuation multiples. MGTX trades at 64.1x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (-7.0% FCF margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MGTX (72.2% ROE) versus DSGN (-36.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MGTX carries 52.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 68% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.